Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas

[1]  Songhua Zhan,et al.  Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI , 2017, Journal of magnetic resonance imaging : JMRI.

[2]  J. Boxerman,et al.  Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)‐MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab , 2016, Journal of magnetic resonance imaging : JMRI.

[3]  J L Boxerman,et al.  Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange , 2016, American Journal of Neuroradiology.

[4]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[5]  M. Muti,et al.  High- and low-grade glioma differentiation: the role of percentage signal recovery evaluation in MR dynamic susceptibility contrast imaging , 2015, La radiologia medica.

[6]  K. Aldape,et al.  IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas , 2015, Acta Neuropathologica.

[7]  Jill S. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 , 2015, Neuro-oncology.

[8]  Zhe Zhang,et al.  Lower apparent diffusion coefficients indicate distinct prognosis in low-grade and high-grade glioma , 2014, Journal of Neuro-Oncology.

[9]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[10]  Lihua Chen,et al.  The Correlation between Apparent Diffusion Coefficient and Tumor Cellularity in Patients: A Meta-Analysis , 2013, PloS one.

[11]  L. Deangelis,et al.  Glioblastoma and other malignant gliomas: a clinical review. , 2013, JAMA.

[12]  E. Melhem,et al.  Differentiation between Oligodendroglioma Genotypes Using Dynamic Susceptibility Contrast Perfusion-Weighted Imaging and Proton MR Spectroscopy , 2013, American Journal of Neuroradiology.

[13]  O. Chinot,et al.  Multimodal MR Imaging (Diffusion, Perfusion, and Spectroscopy): Is It Possible to Distinguish Oligodendroglial Tumor Grade and 1p/19q Codeletion in the Pretherapeutic Diagnosis? , 2013, American Journal of Neuroradiology.

[14]  Zhaoshi Jiang,et al.  Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Deb,et al.  Intraoperative neurocytology of primary central nervous system neoplasia: A simplified and practical diagnostic approach , 2011, Journal of cytology.

[16]  M S Brown,et al.  Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma , 2011, American Journal of Neuroradiology.

[17]  Paul S Mischel,et al.  Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.

[18]  P. LaViolette,et al.  Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity , 2010, Journal of magnetic resonance imaging : JMRI.

[19]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[20]  Inas S. Khayal,et al.  Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging. , 2009, Translational oncology.

[21]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[22]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[23]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[24]  Frank M. Sacks,et al.  IDH 1 and IDH 2 Mutations in Gliomas , 2009 .

[25]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[26]  Carol Walker,et al.  Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype , 2007, Journal of magnetic resonance imaging : JMRI.

[27]  Webster K. Cavenee,et al.  Erratum: The 2007 WHO classification of tumours of the central nervous system (Acta Neuropathol (2007) vol. 114 (97-109)) , 2007 .

[28]  D. Reardon,et al.  Diagnosis and treatment of high-grade astrocytoma. , 2007, Neurologic clinics.

[29]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[30]  E. Shaw,et al.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.

[31]  R M Weisskoff,et al.  Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.

[32]  Haruhiko Hoshino.  [Multimodal MR]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[33]  Nancy J Fischbein,et al.  Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. , 2005, AJNR. American journal of neuroradiology.

[34]  R. Fimmers,et al.  Oligodendroglial Tumors: Refinement of Candidate Regions on Chromosome Arm 1p and Correlation of 1p/19q Status with Survival , 2004, Brain pathology.

[35]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[36]  A. Chiò,et al.  The Prognostic Role of Vessel Productive Changes and Vessel Density in Oligodendroglioma , 1999, Journal of Neuro-Oncology.

[37]  M. J. van den Bent,et al.  Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features , 2003, Cancer.

[38]  B. Scheithauer,et al.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  E F Halpern,et al.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.